BioSpace News Archive

Agios Pharmaceuticals, Inc. today announced that the company is scheduled to present at the following September investor conferences: Wells Fargo Healthcare Conference on Wednesday, September 7, 2022 at 8:35 a.m. ET; and Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 4:50 p.m.

Covalon Technologies Ltd. will release its Q3 Fiscal 2022 financial results on Monday, August 29th, 2022, before markets open.

Nimbus Therapeutics today presented research describing the chemical structure of NDI-034858, the company’s investigational oral allosteric TYK2 (tyrosine kinase 2) inhibitor now in two Phase 2b clinical studies for moderate-to-severe plaque psoriasis.

Ainos, Inc. today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19.

Annovis Bio, Inc. announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson’s Disease (PD) has been dosed.

Make-A-Wish America today announced that the board of directors has appointed Leslie Motter as the organization’s new president and CEO, as current President and CEO Richard Davis steps down to begin his retirement.

BetterLife Pharma Inc., is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.

Assembly Biosciences, Inc. plans to host a research webcast on Wednesday, August 31, 2022, from 1:30-2:30 pm PT/4:30-5:30 pm.

Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601.